Explore our archive of news and updates from the HS Foundation — a curated collection of stories, milestones, and announcements from over the years.

New Study Explores Tunnel-Targeted Antimicrobial Gel for HS Treatment

July 11, 2025

A newly published prospective study in JAAD highlights a novel approach for treating Hidradenitis Suppurativa using a topical clindamycin gel delivered directly into tunnels. The treatment showed promising results in reducing inflammation, resolving tunnels, restoring microbial balance, and improving quality of life. Led by researchers at the University of Miami, including HSF President Dr. Hadar Lev-Tov, this work offers new insights into localized therapies for HS.
Read more

---

Dermatologic Procedures for Hidradenitis Suppurativa

July 10, 2025

Explore how dermatologic procedures like deroofing, excision, and laser therapies are helping patients with hidradenitis suppurativa achieve better outcomes. This article highlights expert insights on selecting the right approach based on severity, recurrence, and patient goals.
Read more

---

Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa

July 2, 2025

A newly published living systematic review and network meta-analysis in JAMA Dermatology offers an in-depth look at the current evidence on medical therapies for HS. This important research helps inform treatment decisions and highlights the growing momentum in HS clinical trials.
Read more

---

Spironolactone for Hidradenitis Suppurativa: A Game-Changer for Women of Childbearing Age?

June 30, 2025

Could spironolactone be a game-changer for women with early-stage HS? A recent study found that while only 1 in 5 women of childbearing age saw improvement with the hormone-blocking drug, those with milder disease and earlier treatment were far more likely to benefit. This research offers valuable insight into tailoring HS treatment for patients most likely to respond.
Read more

---

Deroofing – Safe and Effective for HS Patients

June 18, 2025

A new study highlights the safety and effectiveness of deroofing—a surgical treatment for hidradenitis suppurativa. Among 44 patients, only 12% of lesions returned within a year, and most reported less pain and better quality of life. While further research is needed, these results suggest deroofing may be a valuable option, even alongside systemic therapies.
Read more

---

Semaglutide for diabetes, weight loss, and… Hidradenitis Suppurativa?

April 28, 2025

Could a popular weight loss and diabetes drug also help treat hidradenitis suppurativa? See what researchers discovered about semaglutide’s surprising potential.
Read more

---

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppura

March 18, 2025

Incyte announced positive Phase 3 results for povorcitinib in hidradenitis suppurativa, with both trials meeting their primary endpoint of reducing inflammatory nodules.
Read more

---

Links Between Plastics Use, Processed Food, Sweating, and Hidradenitis Suppurativa

March 5, 2025

Could everyday habits like diet, plastic use, and sweating play a role in HS? This study uncovers intriguing connections that may shape our understanding of the condition.
Read more

---

SHSA 2024 Abstracts Now Published in Dermatology and Therapy!

February 19, 2025

The research presented at SHSA 2024 is now accessible to the global dermatology community! Explore the latest findings in Hidradenitis Suppurativa, now published in Dermatology and Therapy.
Read more

---

British Journal of Dermatology Releases Hidradenitis Suppurativa Supplement

February 5, 2025

The British Journal of Dermatology has released a comprehensive Hidradenitis Suppurativa Supplement in its February 2025 issue. This special edition features state-of-the-art reviews and research articles from leading experts, offering new insights into disease mechanisms, treatment options, and patient care strategies. Explore the latest advancements in understanding and managing this chronic skin condition.
Read more

---

North American Clinical Practice Guidelines for the Medical Management of Hidradenitis Suppurativa in Special Patient Population

January 14, 2025

New evidence-based guidelines are now available to help clinicians manage Hidradenitis Suppurativa in vulnerable populations, including women, adolescents, and individuals with chronic conditions. This important resource is made possible by the hard work of many individuals, including several current HS Foundation leaders.
Read more

---

Hidradenitis Suppurativa and Maternal and Offspring Outcomes

January 9, 2025

How does Hidradenitis Suppurativa during pregnancy impact the health of mothers and their newborns both immediately and long-term?
Read more

---

Analysis of ChatGPT’s Responses to Patient Questions on Hidradenitis Suppurativa

January 8, 2025

A recent study revealed that while AI tools like ChatGPT can provide health information, responses from the HS Foundation website are more readable, accurate, and reliable for patients seeking guidance. This information emphasizes that relying on AI for medical advice can come with risks, as it may lack the clarity and nuance provided by expert-reviewed resources. At HSF, we are dedicated to being the world's most trusted resource for expert information on HS, empowering patients and providers with accurate, evidence-based insights.
Read more

---

UCSF-led Study Aims to Improve Treatment of Painful Skin Disease

December 18, 2024

HS Foundation Vice President, Dr. Haley Naik, just announced a collaboration with UCB USA and UCSF -led HS PROGRESS (Hidradenitis Suppurativa PRospective Observational REgistry and bioSpecimen repoSitory). This collaboration will help support the registry's efforts to accelerate development of treatment options for the condition. The HSF is proud to have provided seed funding for HS PROGRESS from 2020-2022, and we are excited to see the widespread positive impact this resource will have on the entire HS community.
Read more

---

Hidradenitis suppurativa: Embracing progress

December 1, 2024

The HS Foundation has partnered with the AAD Member to publish "Hidradenitis Suppurativa: Embracing Progress" in the December issue of the Journal of the American Academy of Dermatology (JAAD). This supplement highlights the latest advancements in HS research and care. While JAAD content is typically available to subscribers only, our partnership ensures this supplement is free to access for everyone for the next six months! HSF Board Members Drs. Chris Sayed and Jennifer Hsiao served as co-editors on the supplement, which features content submitted by many HS Foundation leaders and volunteers.
Read more

---

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with modera

November 20, 2024

This week, the FDA announced the approval of bimekizumab-bkzx (Bimzelx), developed by UCB USA, for the treatment of moderate to severe Hidradenitis Suppurativa (HS) in adults. Bimzelx is the first dual IL-17 inhibitor approved for HS, marking a groundbreaking step forward in treatment options. This is the third FDA-approved therapy for HS—and the second in just 13 months—signaling incredible momentum in research and care for those living with HS.
Read more

---

American Academy of Dermatology launches innovative project to improve outcomes for patients with hidradenitis suppurativa

October 30, 2024

The American Academy of Dermatology (AAD) has launched a groundbreaking initiative to improve outcomes for those living with Hidradenitis Suppurativa (HS). By focusing on education, collaboration, and best practices, this project aims to empower dermatologists and enhance patient care.
Read more

---